Known as Fast Virological Response or RVR.

Anadys Pharmaceuticals reviews positive 4-week results from its ANA598 Phase II research for HCV Anadys Pharmaceuticals, Inc. today announced preliminary outcomes from a well planned interim analysis of data at a month for the first dosage cohort, 200 mg bid, within an ongoing Phase II research of ANA598 in conjunction with pegylated interferon and ribavirin in HCV patients. 56 percent of individuals receiving ANA598 plus SOC achieved undetectable degrees of virus at week 4, known as Fast Virological Response or RVR, compared to 20 percent of sufferers receiving placebo plus SOC tablets dose . ANA598 was well tolerated through four weeks, with no serious adverse events reported. An independent Data Monitoring Committee provides endorsed escalating to the second dosage level, 400 mg bid, which cohort is currently open for enrollment.